Overview: Chromogranin A (CgA) TestIntroduction: The Chromogranin A Test measures chromogranin A to diagnose neuroendocrine tumors, causing flushing or diarrhea. Following 2023 NCCN guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment monitoring, and improving outcomes in immunology for patients with suspected neuroendocrine tumors.
Other Names: CgA Assay, Neuroendocrine Tumor Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Chromogranin A testing began in the 1980s with neuroendocrine tumor research. Immunoassays emerged in the 1990s, and by the 2000s, high-sensitivity assays improved diagnostic accuracy.
Purpose: Diagnoses neuroendocrine tumors, guides treatment, and monitors chromogranin A levels in patients with flushing or diarrhea.
Test Parameters: 1. Chromogranin A
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like flushing or diarrhea, and list medications like proton pump inhibitors.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document flushing, diarrhea, or family history of neuroendocrine tumors. Include current medications, especially proton pump inhibitors or chemotherapy.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer treatment.
Procedural Considerations: Uses an immunoassay to measure chromogranin A levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Proton pump inhibitors or renal failure may elevate CgA levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated CgA levels indicate neuroendocrine tumors, prompting imaging or surgery. Normal levels suggest alternative diagnoses.
Specialist Consultation: Consult an oncologist for result interpretation. An endocrinologist referral is advised for neuroendocrine tumor cases.
Additional Supporting Tests: 5-HIAA urine test, PET scan, or octreotide scan to confirm neuroendocrine tumors or assess disease extent.
Test Limitations: False positives may occur with benign conditions. Results require clinical correlation with imaging.
References: NCCN Neuroendocrine Tumor Guidelines, 2023; Journal of Clinical Oncology, Yao JC, 2022.
